1.
Br J Haematol
; 201(2): 353-356, 2023 04.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36793194
2.
Ugeskr Laeger
; 186(4)2024 01 22.
Artigo
em Dinamarquês
| MEDLINE
| ID: mdl-38305321
RESUMO
During the last two decades, novel targeted therapies, in particular, ¼small molecules« for oral administration and monoclonal antibodies, have revolutionized the treatment and prognosis of haematological cancers. Generally, these treatments are well tolerated and therefore suitable for elderly patients. This review presents a short update on the current standard-of-care treatment of elderly patients with haematological cancer.